Search clinical trials for: XGEVA

Total 64 results

RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Natasha Appelman-Dijkstra

Recruiting

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) (DeFiD)

Fibrous Dysplasia | McCune Albright Syndrome

Netherlands
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Healthy

China
Luye Pharma Group Ltd.

Recruiting

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Australian and New Zealand Intensive Care Research...

Recruiting

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (BoneZone)

Critical Illness | Osteoporosis

Australia, New Zealand
Amgen

Recruiting

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Giant Cell Tumor of Bone

Taiwan, China
University of Colorado, Denver

Recruiting

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Carcinoma, Non-Small-Cell Lung

United States
Leiden University Medical Center
Amgen

Recruiting

Denosumab in Subjects With Giant Cell Rich Tumors of Bone

Aneurysmal Bone Cysts | Giant Cell Granuloma | Osteoblastoma | Chondroblastoma | Chondromyxoid Fibroma

France, Italy, Netherlands
Assistance Publique - Hôpitaux de Paris
CEREMAST

Completed

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis (DenosuMast)

Osteoporosis | Systemic Mastocytosis

France
ETOP IBCSG Partners Foundation
European Organisation for Research and Treatment of Cancer - EORTC; Amgen

Terminated

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (SPLENDOUR)

Lung Cancer Non-small Cell Stage IV

Ireland, Spain, Switzerland, United Kingdom, France, Austria, Slovenia, Belgium, Italy, Germany, Poland
UNC Lineberger Comprehensive Cancer Center
Amgen

Completed

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Melanoma | Melanoma (Skin) | Melanoma Stage Iv | Melanoma Stage Iii | Cutaneous Melanoma

United States
Alvotech Swiss AG

Active, not recruiting

AVT03 With Xgeva in Healthy Male Subjects

This is a Phase Study Conducted in Healthy Volunteers

South Africa
Taizhou Mabtech Pharmaceutical Co.,Ltd

Withdrawn

Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers

Healthy Volunteers

China
Swiss Group for Clinical Cancer Research

Active, not recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

Switzerland, Germany, Austria
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Terminated

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

Spinal Cord Injury | Secondary Osteoporosis

United States
Roswell Park Cancer Institute
Amgen

Completed

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Osteoporosis | Osteopenia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico
Arbeitsgemeinschaft medikamentoese Tumortherapie
Amgen; Assign Data Management and Biostatistics GmbH

Active, not recruiting

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (DEFENCE)

Multiple Myeloma

Austria, Germany, Israel
Amgen
Aarhus University Hospital

Completed

Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid

Osteonecrosis of the Jaw | Infection Leading to Hospitalization
mAbxience Research S.L.

Completed

A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva

Healthy Volunteers

Poland
Cancer Trials Ireland

Terminated

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. (DICE)

Metastatic Cancer | Bone Metastases | Castration-resistant Prostate Cancer

Ireland
Australian and New Zealand Urogenital and Prostate...
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)

Renal Cell Carcinoma, Clear Cell | Metastatic Kidney Cancer

Australia
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
Elizabeth Shane
Creighton University

Completed

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Adult Idiopathic Generalized Osteoporosis

United States
Amgen

Completed

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

GCT | Giant Cell Tumor of Bone
Amgen
Daiichi Sankyo, Inc.

Completed

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Cancer | Multiple Myeloma | Bone Metastases | Hematologic Malignancies | Oncology | Multiple Myeloma Bone Lesions

United States, Germany, Italy, Spain, Canada, France, Czechia, Hungary, Korea, Republic of, Russian Federation, United Kingdom, Taiwan, Australia, Hong Kong, New Zealand, Austria, Slovakia, Portugal, Greece, Bulgaria, Poland, Ukraine and more
University Medical Centre Ljubljana

Enrolling by invitation

Osteoporosis in Primary Hyperparathyroidism

Primary Hyperparathyroidism | Osteoporosis

Slovenia
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Terminated

Denosumab in Primary Hyperparathyroidism

Primary Hyperparathyroidism

United States
Hellenic Society for the Study of Bone Metabolism

Completed

Denosumab for the Treatment of Adult LCH

Langerhans Cell Histiocytosis

Greece
National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
Alison Stopeck
Amgen

Completed

Denosumab and MRI Breast Imaging (Dmab)

Breast Cancer

United States
University Health Network, Toronto
Amgen

Completed

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Kidney Cancer | Bladder Cancer | Urothelial Carcinoma | Ureter Cancer

Canada
Institut Català d'Oncologia
Amgen

Active, not recruiting

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer (D-BIOMARK)

Stage I Breast Cancer | Breast Neoplasm Female | Stage II Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Neoplasm

Spain
Amgen

Completed

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, Italy, Netherlands, Canada, United Kingdom, Australia, Germany, Czechia, Greece, France
Amgen
Daiichi Sankyo, Inc.

Terminated

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Breast Cancer

United States, Denmark, France, Italy, Belgium, Canada, Czechia, Germany, Netherlands, United Kingdom, Korea, Republic of, Peru, Philippines, Poland, Russian Federation, Taiwan, Spain, Australia, Hong Kong, Slovakia, Israel, Hungary, Portug... and more
Peter Vestergaard
Aalborg University

Completed

Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. (DENOCINA)

Primary Hyperparathyroidism | Parathyroid Adenoma | Parathyroid Hyperplasia

Denmark
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (MW032)

Bone Tumor

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm

United States
Massachusetts General Hospital
Emory University; University of Rochester; Amgen; University Hospitals Cleveland...

Unknown

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Multiple Myeloma

United States
European Organisation for Research and Treatment...
Amgen

Terminated

Reduced Dose-density of Denosumab for Unresectable GCTB (REDUCE)

Bone Giant Cell Tumor

Spain, United Kingdom, Italy, Netherlands
Qilu Pharmaceutical Co., Ltd.

Unknown

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Bone Metastases

China
NYU Langone Health

Completed

Presurgical Trial of Denosumab in Breast Cancer

Breast Cancer

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Bone Metastasis From Solid Tumors
Washington University School of Medicine

Completed

RANKL Inhibition and Breast Tissue Biomarkers

Breast Cancer Prevention | Mammographic Density

United States
Borstkanker Onderzoek Groep
Amgen

Withdrawn

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer (PERIDENO)

Breast Neoplasms

Netherlands
Hope Rugo, MD
University of California, San Francisco; Amgen

Terminated

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Early Stage Breast Cancer

United States
Luye Pharma Group Ltd.
Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Unknown

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Healthy Adults
Qilu Pharmaceutical Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Healthy People

China
Amgen

Completed

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer

Spain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama

Search clinical trials for: XGEVA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations